Literature DB >> 29958025

Duration of Catheter Use in Patients with Diabetes Using Continuous Subcutaneous Insulin Infusion: A Review.

Lisa Bonato1, Nadine Taleb1,2, Véronique Gingras1,3, Virginie Messier1, Fernand Gobeil4,5, Julie Ménard5, Jean-Luc Ardilouze5,6, Rémi Rabasa-Lhoret1,3,7.   

Abstract

Increasing proportions of patients with diabetes use continuous subcutaneous insulin infusion (CSII) therapy mostly due to its clinical efficacy and flexibility for insulin dosing and adjustments. Some challenges are nevertheless associated with this technology. A key and underlooked component of CSII technical difficulties is the subcutaneous catheter used to infuse insulin. Several adverse events (AEs) have been experienced by patients in relation to catheters, such as blockage, kinking, and insertion site reactions, including irritation, infections, lipohypertrophies etc., all of which could compromise the metabolic control. With the objective of minimizing these AEs, recommendations for changing catheters every 2-3 days have historically been provided by manufacturers based on reports derived from small studies and anecdotal data. The aim of this review was to provide an updated analysis of current recommendations and patients' practices in relation to frequency of catheter change. Our main findings are: (1) adequately designed and powered studies investigating optimal catheter wearing time are still lacking; (2) increasing catheter wearing time is generally associated with increased frequency of catheter AEs; (3) however, interpatient variability is large, with some individuals needing to change their catheters every 2-3 days, whereas others probably being able to keep them in place for longer periods without problems. Further research is thus warranted to provide more solid and evidence-based recommendations while exploring personalized approaches at the same time. Increasing catheter wear life without significant side effects is an important goal to simplify CSII therapy and reduce its associated costs and burdens.

Entities:  

Keywords:  Cannula; Catheter; Catheter adverse events; Catheter wear time; Continuous subcutaneous insulin infusion; Insulin pumps

Mesh:

Substances:

Year:  2018        PMID: 29958025     DOI: 10.1089/dia.2018.0110

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  5 in total

1.  Five-Month Follow-up Shows No Improvement in Dermatological Complications in Children With Type 1 Diabetes Using Continuous Glucose Monitoring Systems and Insulin Pumps.

Authors:  Anna T Weng; Claus Zachariae; Karl B Christensen; Jannet Svensson; Anna K Berg
Journal:  J Diabetes Sci Technol       Date:  2019-10-16

2.  Improving the Patient Experience With Longer Wear Infusion Sets Symposium Report.

Authors:  Kevin T Nguyen; Nicole Y Xu; Bruce A Buckingham; Sarnath Chattaraj; Ohad Cohen; Lutz Heinemann; John Pickup; Jannet Svensson; Robert A Vigersky; Jenise C Wong; Ralph Ziegler
Journal:  J Diabetes Sci Technol       Date:  2022-02-28

3.  Survival assessment of the extended-wear insulin infusion set featuring lantern technology in adults with type 1 diabetes by the glucose clamp technique.

Authors:  Amra Simic; Pernelle K Schøndorff; Tobias Stumpe; Matthias Heschel; Werner Regittnig; Tina Pöttler; Daniela Ninaus; Thomas Augustin; Andrea Groselj-Strele; Thomas R Pieber; Julia K Mader
Journal:  Diabetes Obes Metab       Date:  2021-03-04       Impact factor: 6.577

4.  Subcutaneous vitamin B12 administration using a portable infusion pump in cobalamin-related remethylation disorders: a gentle and easy to use alternative to intramuscular injections.

Authors:  Amelie S Lotz-Havla; Katharina J Weiß; Katharina A Schiergens; Theresa Brunet; Jürgen Kohlhase; Stephanie Regenauer-Vandewiele; Esther M Maier
Journal:  Orphanet J Rare Dis       Date:  2021-05-12       Impact factor: 4.123

5.  Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients.

Authors:  Stefano Passanisi; Giuseppina Salzano; Francesca Galletta; Sara Aramnejad; Lucia Caminiti; Giovanni B Pajno; Fortunato Lombardo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-15       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.